Copper (64Cu) oxodotreotide

（64铜）铜氧奥曲肽

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameCopper (64Cu) oxodotreotide
Drug Alias NameCopper Cu 64 dotatate64Cu-DOTATATE64Cu-octreotateCOPPER CU 64 DOTATATE64Cu-DOTA-[3-Tyr]-octreotate +[6] 
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Copper > 64Cu +[5] 
Mechanisms of ActionSomatostatin receptor modulatorsIonising radiation emitters
TargetsSomatostatin receptor
Therapy Area/IndicationsNeuroendocrine Tumors
Global Approved IndicationsNeuroendocrine Tumors
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/09/03
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRadiomedix Inc
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Huayi Nuclear Medicine Co LtdCurium IncCurium Us Llc +[4] 
Inactive CompaniesRadiomedix Inc
Active IndicationsNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeL01XX
Related LinksWikipediaKEGG